{"id":"tacrolimus-accord","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nephrotoxicity"},{"rate":"20-40","effect":"Hypertension"},{"rate":"10-25","effect":"Hyperglycemia/new-onset diabetes"},{"rate":"5-15","effect":"Neurotoxicity (tremor, headache)"},{"rate":"15-30","effect":"Infection"},{"rate":"5-15","effect":"Hyperkalemia"},{"rate":"5-10","effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin, a serine/threonine phosphatase essential for dephosphorylating NFAT (nuclear factor of activated T cells). By preventing NFAT nuclear translocation, tacrolimus suppresses the transcription of IL-2 and other cytokines required for T-cell proliferation and immune response. This potent immunosuppressive effect makes it valuable in transplantation and autoimmune conditions.","oneSentence":"Tacrolimus inhibits calcineurin phosphatase, blocking T-cell activation and proliferation by preventing IL-2 transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:44.526Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (kidney, heart, liver)"},{"name":"Atopic dermatitis"},{"name":"Autoimmune conditions (off-label use in various settings)"}]},"trialDetails":[{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT01203722","phase":"PHASE1, PHASE2","title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-09","conditions":"Hematologic Malignancies","enrollment":87},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":"Immunodeficiency, Hematopoietic Stem Cell Transplantation","enrollment":54},{"nctId":"NCT03467386","phase":"PHASE1","title":"Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2018-03-19","conditions":"Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT07104799","phase":"PHASE1","title":"Momelotinib During and After HCT in Myelofibrosis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-01-01","conditions":"Myelofibrosis, Hematopoietic Cell Transplantation (HCT)","enrollment":28},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT02891603","phase":"PHASE1, PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":"Graft Vs Host Disease, GVHD","enrollment":40},{"nctId":"NCT04182984","phase":"","title":"TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2019-11-04","conditions":"Ocular Myasthenia Gravis","enrollment":200},{"nctId":"NCT03842696","phase":"PHASE1, PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":"Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":43},{"nctId":"NCT06084780","phase":"PHASE2","title":"Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-02","conditions":"Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei","enrollment":20},{"nctId":"NCT07307534","phase":"NA","title":"Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-01-20","conditions":"Vitiligo, Halo Nevus","enrollment":60},{"nctId":"NCT03121014","phase":"PHASE2","title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-04-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT03605927","phase":"PHASE1","title":"CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-02-15","conditions":"Graft-versus-host-disease, GVHD, GVHD, Acute","enrollment":45},{"nctId":"NCT04629248","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Primary Membranous Nephropathy","enrollment":142},{"nctId":"NCT07203664","phase":"PHASE4","title":"Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus.","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitario La Paz","startDate":"2025-10-30","conditions":"Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients","enrollment":30},{"nctId":"NCT07049172","phase":"NA","title":"Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome","status":"COMPLETED","sponsor":"Wuhan Children's Hospital","startDate":"2021-01-01","conditions":"Nephrotic Syndrome in Children","enrollment":91},{"nctId":"NCT02630628","phase":"PHASE3","title":"Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-12-05","conditions":"Lupus Nephritis","enrollment":130},{"nctId":"NCT00552201","phase":"PHASE4","title":"TACrolimus in Renal Transplantation: Individualization by Pharmacogenetic","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2006-04","conditions":"Kidney Transplantation","enrollment":280},{"nctId":"NCT04339777","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-22","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases","enrollment":66},{"nctId":"NCT06701825","phase":"PHASE4","title":"Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus","status":"RECRUITING","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2025-06-02","conditions":"Kidney Disease, Chronic, Transplant Recipient (Kidney), Immunosuppression","enrollment":114},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT06829719","phase":"NA","title":"TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-23","conditions":"Infection, Cancer, Rejection","enrollment":300},{"nctId":"NCT06900777","phase":"NA","title":"Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-04-01","conditions":"Vitiligo, Child, Progressive Disease","enrollment":90},{"nctId":"NCT03726307","phase":"PHASE1","title":"Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Angus W. Thomson PhD DSc","startDate":"2019-04-10","conditions":"Kidney Transplant, Renal Transplant Recipients","enrollment":28},{"nctId":"NCT06235892","phase":"PHASE3","title":"Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-12-10","conditions":"Organ Grafts","enrollment":332},{"nctId":"NCT06080490","phase":"","title":"Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2023-09-29","conditions":"Graft Vs Host Disease, Transplant Failure, Stem Cell Transplant Complications","enrollment":125},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT05365672","phase":"PHASE2","title":"Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation","status":"RECRUITING","sponsor":"TolerogenixX GmbH","startDate":"2022-05-04","conditions":"Kidney Transplantation","enrollment":126},{"nctId":"NCT04198506","phase":"NA","title":"Viral Load Guided Immunosuppression After Lung Transplantation","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2020-08-05","conditions":"Transplantation Lung","enrollment":146},{"nctId":"NCT04665310","phase":"PHASE4","title":"Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-09-01","conditions":"Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant","enrollment":46},{"nctId":"NCT05298358","phase":"PHASE1","title":"RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-11-18","conditions":"Systemic Sclerosis","enrollment":1},{"nctId":"NCT06183892","phase":"NA","title":"Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-03-04","conditions":"Liver Transplant","enrollment":80},{"nctId":"NCT05655273","phase":"PHASE4","title":"Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"University Health Network, Toronto","startDate":"2024-01-01","conditions":"Liver Transplant Rejection, Immune System Suppression","enrollment":40},{"nctId":"NCT03413722","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-01","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT04701528","phase":"PHASE2","title":"Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2020-11-15","conditions":"Covid19, Kidney Transplant Infection","enrollment":20},{"nctId":"NCT02014103","phase":"PHASE4","title":"Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2015-03","conditions":"Complication of Transplant","enrollment":71},{"nctId":"NCT03225417","phase":"PHASE1, PHASE2","title":"Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2017-05-16","conditions":"Hematopoietic Stem Cell Transplantation, Multiple Myeloma","enrollment":142},{"nctId":"NCT05744635","phase":"","title":"Assessment of the Pharmacokinetic Profile of Tacrolimus Medications and Their Relation to Effectiveness and Safety in Liver Transplant Patients","status":"RECRUITING","sponsor":"Chiesi Hungary Ltd.","startDate":"2023-05-10","conditions":"Liver Failure","enrollment":110},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT06268769","phase":"PHASE4","title":"Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs","status":"RECRUITING","sponsor":"Edward Geissler","startDate":"2024-03-09","conditions":"Immunosuppression","enrollment":300},{"nctId":"NCT01428973","phase":"PHASE2","title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liege","startDate":"2011-09","conditions":"Graft-Versus-Host Disease, Hematological Malignancies","enrollment":200},{"nctId":"NCT05807932","phase":"PHASE1, PHASE2","title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2023-06-26","conditions":"Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":38},{"nctId":"NCT01751997","phase":"PHASE2, PHASE3","title":"Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors","status":"COMPLETED","sponsor":"Byung-Sik Cho","startDate":"2013-01","conditions":"Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT03959241","phase":"PHASE3","title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-06-25","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia","enrollment":431},{"nctId":"NCT06319391","phase":"","title":"Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ziqiang Li","startDate":"2023-04-01","conditions":"Complete and Accurate Statistical Data of 60 Patients, CYP3A5*3 Genotypes of 60 Donors and Recipients Were Analyzed Accurately, Postoperative Tacrolimus Concentrations Were Accurately Recorded in 60 Patients","enrollment":60},{"nctId":"NCT06178146","phase":"PHASE4","title":"Thymosin Alpha-1 for irAE Secondary to ICIs","status":"UNKNOWN","sponsor":"Jun Wang","startDate":"2023-09-01","conditions":"IrAE","enrollment":40},{"nctId":"NCT06147648","phase":"PHASE4","title":"Early Conversion of Prolonged-release Tacrolimus in Liver Transplantation.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-12-01","conditions":"Liver Transplantation","enrollment":352},{"nctId":"NCT04725682","phase":"PHASE1","title":"Bioequivalence Study of Tacrolimus in Healthy Volunteers","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2021-01-05","conditions":"Healthy Volunteers","enrollment":67},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT05913596","phase":"NA","title":"The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-05-23","conditions":"Antibody-mediated Rejection, Kidney Tranplant","enrollment":15},{"nctId":"NCT04414735","phase":"NA","title":"Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Kidney Transplant Rejection","enrollment":30},{"nctId":"NCT00057954","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-11-09","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT02936505","phase":"NA","title":"Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2016-10-12","conditions":"Lung Transplantation, Allografts","enrollment":249},{"nctId":"NCT04903054","phase":"PHASE2","title":"Selective CD28 Blockade in Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-01-10","conditions":"Kidney Transplantation, Renal Transplant Recipients","enrollment":""},{"nctId":"NCT02345850","phase":"PHASE3","title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Acute Leukemia, Myelodysplasia","enrollment":346},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":"Transplant; Failure, Kidney, EBV","enrollment":28},{"nctId":"NCT04403321","phase":"PHASE2","title":"Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2020-07-01","conditions":"Aplastic Anemia, Drug Effect","enrollment":114},{"nctId":"NCT02909335","phase":"PHASE3","title":"De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT02158052","phase":"NA","title":"Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-02","conditions":"Multiple Myeloma, Amyloidosis","enrollment":2},{"nctId":"NCT05274308","phase":"","title":"Stability of Tacrolimus, Cyclosporine A, Everolimus and Sirolimus in Whole Blood Patient Samples","status":"COMPLETED","sponsor":"Thermo Fisher Scientific Oy","startDate":"2022-02-07","conditions":"Transplantation Drugs Stability","enrollment":46},{"nctId":"NCT05532111","phase":"NA","title":"Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-09-01","conditions":"Efficacy and Safety","enrollment":60},{"nctId":"NCT02495077","phase":"PHASE2","title":"Effects of Inhibiting Early Inflammation in Kidney Transplant Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-02","conditions":"Kidney Transplant","enrollment":290},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT04444843","phase":"PHASE4","title":"Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-01-22","conditions":"Kidney Transplant Recipients","enrollment":300},{"nctId":"NCT03099122","phase":"PHASE4","title":"A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-08-16","conditions":"End-stage Renal Disease","enrollment":115},{"nctId":"NCT04657562","phase":"","title":"The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma","status":"UNKNOWN","sponsor":"National Science Centre, Poland","startDate":"2020-08-01","conditions":"Immunosuppression, Kidney Transplant Rejection, Kidney Transplant; Complications","enrollment":380},{"nctId":"NCT04973982","phase":"NA","title":"ENvarsus for Impaired Glucose Tolerance Post REnal transplAnT","status":"WITHDRAWN","sponsor":"Barts & The London NHS Trust","startDate":"2022-01-31","conditions":"Renal Transplant Failure","enrollment":""},{"nctId":"NCT00931255","phase":"PHASE4","title":"Tacrolimus to Sirolimus Conversion for Delayed Graft Function","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2009-04","conditions":"Kidney Transplant, Delayed Graft Function","enrollment":32},{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT01729494","phase":"PHASE4","title":"Belatacept Early Steroid Withdrawal Trial","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-09","conditions":"Renal Transplantation","enrollment":316},{"nctId":"NCT01768845","phase":"NA","title":"Unrelated Umbilical Cord Blood (UBC)Transplantation","status":"COMPLETED","sponsor":"West Virginia University","startDate":"2009-02-03","conditions":"Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome","enrollment":34},{"nctId":"NCT03703154","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-10-25","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT01653847","phase":"NA","title":"Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2013-02","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":88},{"nctId":"NCT04765826","phase":"NA","title":"Comparison Between Systemic Steroids, Topical Steroids, or Calcineurin Inhibitors With Mini Punch Grafting in Treatment of Stable Non-segmental Vitiligo","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2021-01-25","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT01820572","phase":"PHASE3","title":"A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-27","conditions":"Kidney Transplantation","enrollment":446},{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT00504348","phase":"PHASE2, PHASE3","title":"Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus","status":"COMPLETED","sponsor":"Tokyo Medical and Dental University","startDate":"2007-07","conditions":"Interstitial Pneumonitis, Polymyositis, Dermatomyositis","enrollment":25},{"nctId":"NCT01713400","phase":"PHASE2","title":"Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-25","conditions":"Graft vs. Host Disease","enrollment":54},{"nctId":"NCT02167958","phase":"PHASE1","title":"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source","status":"COMPLETED","sponsor":"Rafic Farah, MD","startDate":"2015-02-11","conditions":"Leukemia, MDS, Myelofibrosis","enrollment":28},{"nctId":"NCT02080195","phase":"PHASE1, PHASE2","title":"Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09-13","conditions":"Lupus Erythematosus, Graft-versus-host Disease","enrollment":1},{"nctId":"NCT01053221","phase":"PHASE2","title":"Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2006-03","conditions":"Kidney Transplantation","enrollment":16},{"nctId":"NCT03864250","phase":"NA","title":"Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-11-26","conditions":"Tacrolimus, Idiopathic Membranous Nephropathy, Clinical Trial","enrollment":124},{"nctId":"NCT01551212","phase":"PHASE4","title":"Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05-24","conditions":"Liver Transplantation","enrollment":339},{"nctId":"NCT03549663","phase":"NA","title":"Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-07-04","conditions":"Idiopathic Membranous Nephropathy","enrollment":108},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT01888432","phase":"PHASE3","title":"Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-25","conditions":"Liver Transplantation","enrollment":285},{"nctId":"NCT02115113","phase":"PHASE3","title":"REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-28","conditions":"Liver Transplantation","enrollment":78},{"nctId":"NCT02084446","phase":"PHASE4","title":"Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant","status":"COMPLETED","sponsor":"Ronaldo de Matos Esmeraldo, MD","startDate":"2012-12","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":120},{"nctId":"NCT02208037","phase":"PHASE2","title":"Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-08","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia","enrollment":279},{"nctId":"NCT03747614","phase":"PHASE4","title":"Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy","status":"UNKNOWN","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2017-06-30","conditions":"Dry Eye Syndromes, Inflammation, Microvessels","enrollment":20},{"nctId":"NCT02957552","phase":"PHASE1","title":"Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2017-03-10","conditions":"Pediatric Liver Transplantation","enrollment":7},{"nctId":"NCT00709592","phase":"PHASE2","title":"Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2008-07-21","conditions":"Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma","enrollment":42}],"_emaApprovals":[],"_faersSignals":[{"count":10,"reaction":"NAUSEA"},{"count":8,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":7,"reaction":"PYREXIA"},{"count":6,"reaction":"DIARRHOEA"},{"count":6,"reaction":"OFF LABEL USE"},{"count":6,"reaction":"VOMITING"},{"count":4,"reaction":"DRUG LEVEL DECREASED"},{"count":4,"reaction":"HEADACHE"},{"count":4,"reaction":"HOSPITALISATION"},{"count":4,"reaction":"MYOCARDIAL INFARCTION"}],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Accord Healthcare tacrolimus"],"phase":"marketed","status":"active","brandName":"Tacrolimus, Accord","genericName":"Tacrolimus, Accord","companyName":"University of Cincinnati","companyId":"university-of-cincinnati","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus is a small molecule inhibitor of the FK506-binding protein 1A, used in immunosuppressive regimens to prevent rejection in patients with end-stage renal failure who have undergone kidney transplantation. It is typically administered in combination with other immunosuppressants, such as mycophenolate mofetil or everolimus, as part of a reduced-dose regimen.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}